Takeda Turns To M&As To Meet Goal Of Replacing Expiring Drugs
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical plans to acquire some companies and merge with others this year in an effort to beef up its oncology drug pipeline and stave off the impact of expiring patents. Takeda faces a problem in having two promising drugs delayed in development and marketing approval as it faces expirations on other key drugs. Takeda sees patent expiration as its "year 2010 problem" and has been counting on having replacements ready for at least two of its best-selling drugs, Prevacid (lansoprazole) for treating ulcers and Actos (pioglitazone) for diabetes, but each has faced a delay at U.S. FDA. To meet a plan to increase sales by 30 percent in fiscal 2010, Takeda now must look at cancer-fighting drugs of other makers. (Click here for more - a subscription may be required
You may also be interested in...
Takeda Readying To Launch PPI Kapidex Within A Month
TOKYO - Takeda expects to launch within a month its Kapidex (dexlansoprazole) delayed- release capsules for the treatment of gastroesophageal reflux disease, the same proton pump inhibitor class of drugs as its Prevacid, which is scheduled to lose patent protection this year, according to the company's third-quarter earnings call Feb. 3
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.